ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc. (NASDAQ:SCRX) today announced that the U.S. Food & Drug Administration (FDA) has extended to January 2, 2008, the Prescription Drug User Fee Act (PDUFA) date on Sciele's new Sular formulation. The new Sular formulation utilizes SkyePharma's (LSE:SKP) patented Geomatrix ® technology, which is designed to provide a lower dose of Sular for each of its current doses.
